Daniel J. Curran - 11 Jun 2026 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Reporting relationship: Director
Issuer ticker: XLO
Reported as of: 11 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 12 Jun 2026, 16:07:08 UTC
Prior SEC filing: 21 Jan 2026
Source filing: View source filing
Reporting owner signature: /s/ Christopher Frankenfield, Attorney-in-Fact

Key filing fact

Daniel J. Curran filed Form 4 for Xilio Therapeutics, Inc. (XLO) on 12 Jun 2026.

Key facts

This page summarizes Daniel J. Curran's Form 4 filing for Xilio Therapeutics, Inc. (XLO).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 12 Jun 2026, 16:07.

Change

Previous filing in this sequence was filed on 21 Jan 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001887599 Primary reporting owner

Curran Daniel J.

Relationship: Director
Address: 828 WINTER STREET, SUITE 300, WALTHAM
Signature: /s/ Christopher Frankenfield, Attorney-in-Fact
Signature date: 12 Jun 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

XLO transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +5,000
Change %
Price: $0.000000^*
Shares after: 5,000
Date: 11 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 5,000
Exercise price: $7.99
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option was granted on June 11, 2026 and will vest as to 100% of the shares underlying the option on the earlier of (i) June 11, 2027 and (ii) the Issuer's next annual meeting of stockholders following the grant date, subject to the Reporting Person's continued service to the Issuer through the vesting date.